5 trends tracked about this subject — the full history, oldest to newest below.
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
AstraZeneca reports significant Phase III trial wins for Tozorakimab, a COPD drug showing broad benefits for current and former smokers.
Novo Nordisk faces a divergent clinical outlook as its pediatric obesity trials succeed while heart drug programs for CKD suffer setbacks.
Novartis shares climb following positive late-stage trial results for its experimental oral multiple sclerosis drug, Rhapsido.
GSK is advancing a new mRNA flu vaccine to Phase III trials after the candidate outperformed standard vaccinations in earlier testing.